Results of Ranibizumab Treatment of the Myopic Choroidal Neovascular Membrane according to the Axial Length of the Eye

Figure 4

Anatomical outcomes over time for eyes with mCNV with different axial lengths. All groups showed a significant decrease in CRT from baseline to the final 12-month follow-up.